Table 2:

AT Density (HU) by Randomization Arm.

	Tesamorelin Responders (N=193)	Placebo (N=148)	P value
Baseline*
VAT density	−91.2 (8.8)	−91.4 (8.9)	0.80
SAT density	−94.1 (10.7)	−95.3 (10.9)	0.29
26-week change*
VAT density	6.2 (8.7)	0.3 (4.2)	<0.001
SAT density	4.0 (8.7)	0.3 (4.8)	<0.001
	Difference in 26-week change between Tesamorelin vs Placebo
Unadjusted 26-week change⌘	Estimated Slope	95%CI	p-value
VAT density (95% CI)	5.9	(4.5, 7.3)	<0.001
SAT density (95% CI)	3.7	(2.3, 5.2)	<0.001
Adjusted 26-week change**⌘
VAT density (95% CI)	2.3	(0.9, 3.7)	0.001
SAT density (95% CI)	3.5	(2.3, 4.7)	<0.001

^*mean (standard deviation)

^**adjusted for baseline AT density, baseline AT area and change in AT area

^⌘HU effect size estimate and 95% confidence interval

AT=adipose tissue, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, HU=Hounsfield Units